

**MOLECULAR CHARACTERIZATION OF
RIFAMPICIN AND/ OR ISONIAZID RESISTANT
MYCOBACTERIUM TUBERCULOSIS COMPLEX**

A

DISSERTATION

**SUBMITTED TO THE CENTRAL DEPARTMENT OF
MICROBIOLOGY**

TRIBHUVAN UNIVERSITY

**IN PARTIAL FULFILLMENT OF THE REQUIREMENTS
FOR THE
AWARD OF MASTER OF SCIENCE IN MICROBIOLOGY
(ENVIRONMENT AND PUBLIC HEALTH)**

BY

BIJAY KUMAR SHARMA

CENTRAL DEPARTMENT OF MICROBIOLOGY

TRIBHUVAN UNIVERSITY

KIRTIPUR, KATHMANDU, NEPAL

2012

RECOMMENDATION

This is to certify that **Mr. Bijay Kumar Sharma** has completed this dissertation work entitled “**Molecular Characterization of Rifampicin and/ or Isoniazid Resistant *Mycobacterium tuberculosis* Complex**” as a partial fulfillment of the requirements of M. Sc. degree in Microbiology (Environment and Public Health) under our supervision. To our knowledge this work has not been submitted for any other degree.

.....
Dr. Megha Raj Banjara
Lecturer
Central Department of Microbiology
Tribhuvan University
Kathmandu, Nepal

.....
Dr. Bhabana Shrestha
Project Chief,
German Nepal Tuberculosis-
Project (GENETUP)
Kathmandu, Nepal

Date:

CERTIFICATE OF APPROVAL

On the recommendation of **Dr. Megha Raj Banjara and Dr. Bhabana Shrestha**, this dissertation work of **Mr. Bijay Kumar Sharma** is approved for the examination and is submitted to the Tribhuvan University in Partial fulfillment of the requirements for M. Sc. degree in Microbiology (Environment and Public Health).

.....

Dr. Anjana Singh
Head of Department
Central Department of Microbiology
Tribhuvan University
Kathmandu, Nepal

Date:

BOARD OF EXAMINERS

Recommended by:

Dr. Megha Raj Banjara
Supervisor

.....
Dr. Bhabana Shrestha
Supervisor

Approved by:

Dr. Anjana Singh
Head of Department

Examined by:

External examiner

.....
Internal Examiner

Date:

ACKNOWLEDGEMENTS

It gives me an immense pleasure to express heartfelt appreciation and an enormous debt to my supervisors Dr. Megha Raj Banjara, Lecturer, Central Department of Microbiology and Dr. Bhabana Shrestha, Chief Medical Officer of German Nepal Tuberculosis Project (GENETUP) for their invaluable guidance, motivation, all time technical support and valuable suggestions received during entire research period.

I would like to express my sincere and profound gratitude, and earnest compliment to Associate Prof. Dr. Dwij Raj Bhatta, Head of Department, Central Department of Microbiology, Tribhuvan University for his all long guidance, tremendous support and constant inspiration.

I would like to express my special thanks to Mr. Bhagwan Maharjan, Head of the project laboratory for providing all laboratory services required for this study and for their kind co-operation during the study in this health project. I am also indebted to all the staff members of this project. I am also indebted to Mr. Sashi Kumar Upadhyaya, Vice Treasurer of Nepal Anti-Tuberculosis Association (NATA).

I am greatly gratified to my guardians for providing unconditional support throughout the study without which this work would not have been completed.

Finally, I am obliged to the University Grants Commission (UGC) for providing financial support.

Date:

.....

Bijay Kumar Sharma

ABSTRACT

Introduction: The ability to rapidly and accurately detect drug resistance in *Mycobacterium tuberculosis* complex (MTBC) isolates is critical for the appropriate treatment of patients suffering from TB and the effectiveness of TB control programs. GenoType MTBDRplus will allow rapid confirmation of TB through the identification of genetic mutations associated with rifampicin and isoniazid resistance. Therefore, this study provides genetic information of isoniazid and rifampicin drug resistance TB isolates in Nepal.

Objectives: To rapidly identify drug resistant TB in cultured specimen through the identification of genetic mutations associated with rifampin and isoniazid resistance in *Mycobacterium tuberculosis* complex (MTBC) isolates.

Methods: Fluorescence microscopy was performed on 62 suspected tuberculosis specimen followed by their culture on Lowenstein–Jensen medium for detection of *Mycobacterium tuberculosis*. Culture specimens were then analysed for identification of rifampicin and /or isoniazid resistance using GenoType MTBDRplus assay.

Results: Among the drug resistant isolates, MDR (multidrug resistance i.e. resistant to at least isoniazid and rifampicin) isolates were predominant (51%). Among all rifampicin resistant isolates, 61.76% of them had mutations in the 530-533 region of *rpoB* gene and was the most common mutation observed as detected by the lack of binding to various wild type probes in the presence of D516V and S531L mutation. More RIF-mono-resistant strains (16.66%) had a D516V mutation (MUT1 band) compared to MDR strains (3.5%). Of all INH resistant strains 96.96% had a mutation in the *katG* gene and 3.03% had a mutation in the *inhA* gene. All isoniazid resistant strains that have mutation in *inhA* gene were found to be multidrug resistant. None of the strains had mutations in both the *katG* and *inhA* genes. S315T1 and S531L were found as the most common mutation for rifampicin and isoniazid respectively.

Conclusions: GenoType MDTBRplus assay can be effectively used for the detection of mutations in most common genes responsible for isoniazid and/or rifampicin resistance.

Keywords: TB, GenoType MTBDRplus, MDR, MTBC.

CONTENTS

Title page	i
Recommendation	ii
Certificate of Approval	iii
Board of Examiners	iv
Acknowledgements	v
Abstract	vi
Contents	vii-viii
List of Tables	ix
List of Figures	x
List of Photographs	xi
Appendices	xii
Abbreviations	xiii
CHAPTER I: INTRODUCTION AND OBJECTIVES	1-5
1.1 Background	1
1.2 Objectives	5
1.2.1 General Objective	5
1.2.2 Specific Objectives	5
CHAPTER II: LITERATURE REVIEW	6-20
2.1 Mycobacteria	6
2.1.1 Genetic diversity	7
2.1.2 Pathogenesis	8
2.2 Tuberculosis and its epidemiology	9
2.2.1 Tuberculosis in Nepal	11
2.3 Tuberculosis diagnosis	12
2.4 Treatment of tuberculosis and mode of action of antitubercular drugs	12
2.4.1 Mode of action of isoniazid and rifampicin	13
2.5 Drug resistance	14
2.5.1 Development of antituberculosis drug resistance	14

2.5.2 Multidrugresistant tuberculosis	16
2.5.3 Drug resistance tuberculosis in Nepal	17
2.6 Detection of drug resistant tuberculosis	17
2.6.1 Drug susceptibility testing	17
2.6.2 Molecular detection technique	18
2.6.3 Line probe assays for tuberculosis drug resistance	19
2.7 Treatment of multidrugresistant tuberculosis	21
2.8 Tuberculosis prevention	22
CHAPTER III: MATERIALS AND METHODS	23-29
3.1 Sample collection	23
3.2 Specimen decontamination	24
3.3 Truant’s staining method	24
3.4 Culture	25
3.5 DNA extraction	25
3.6 PCR of DNA	26
3.7 Hybridization	26
3.8 Interpretation of results	28
3.9 Data analysis	28
Flow chart of procedures	29
CHAPTER IV: RESULTS	30-36
CHAPTER V: DISCUSSION AND CONCLUSION	37-40
CHAPTER VI: SUMMARY AND RECOMMENDATION	41
6.1 Conclusion	41
6.2 Recommendations	42
6.3 Limitations of the study	42
REFERENCES	43-58
APPENDICES	i-x

LIST OF TABLES

Table 1	Amplification profile used during PCR
Table 2	Performance of Genotype MTBDRplus for identification of <i>Mycobacteria</i> type and drug susceptibility result among <i>Mycobacterium tuberculosis</i> complex isolates
Table 3	Sexwise distribution of tuberculosis
Table 4	Regionwise distribution of tuberculosis
Table 5	Age wise distribution of tuberculosis
Table 6	Genotype MTBDRplus test for detection of rifampicin and isoniazid susceptibility pattern among Cat I failure patients
Table 7	Pattern of <i>rpoB</i> gene mutations in resistant <i>Mycobacterium tuberculosis</i> strains
Table 8	Pattern of <i>katG</i> gene mutations in resistant <i>Mycobacterium tuberculosis</i> strains
Table 9	Pattern of <i>inhA</i> gene mutations in resistant <i>Mycobacterium tuberculosis</i> strains
Table 10	Pattern of gene mutations in rifampicin monoresistant <i>Mycobacterium tuberculosis</i> strains
Table 11	Pattern of gene mutations in isoniazid monoresistant <i>Mycobacterium tuberculosis</i> strains
Table 12	Pattern of gene mutations in multidrugresistant <i>Mycobacterium tuberculosis</i> strains
Table 13	Pattern of gene mutations in all rifampicin resistant <i>Mycobacterium tuberculosis</i> strains
Table 14	Pattern of gene mutations in all isoniazid resistant <i>Mycobacterium tuberculosis</i> strains

LIST OF FIGURES

- Figure 1 Estimated TB incidence rates
- Figure 2 Proportion of MDR TB among new TB cases
- Figure 3 Detection of mutations through missing of wild type signals and detection of mutations through presence of mutation signals. *rpoB* wild type probes: WT 1 to WT 8, *rpoB* mutation probes: MUT D516V, H526Y, H526D and S531L.
- Figure 4 The Genotype MTBDRplus kit showing various mutation and wild type probes and respective gene band appearance depending on the drug resistance pattern given by *M. tuberculosis* complex strains

LIST OF PHOTOGRAPHS

- | | |
|--------------|--|
| Photograph 1 | Appearance of gene band in DNA strips observed after hybridization |
| Photograph 2 | Interpretation of results observed in evaluation sheet |

LIST OF APPENDICES

Appendix A	List of equipments and materials
Appendix B	Staining, quality controls and precautions
Appendix C	Clinical and microbiological profile of patient
Appendix D	Molecular assay for detection of drug resistance <i>Mycobacterium</i> strains
Appendix E	Treatment of tuberculosis

ABBREVIATIONS

AFB	Acid Fast Bacilli
AIDS	Acquired Immunodeficiency Syndrome
BSL	Biosafety Level
CAT	Category
DNA	Deoxyribonucleic Acid
DOTS	Directly Observed Treatment Short Course
DR TB	Drug Resistant Tuberculosis
DRS	Drug Resistance Survey
DST	Drug Susceptibility Testing
GENETUP	German Nepal Tuberculosis Project
GLC	Green Light Committee
HIV	Human Immuno-Deficiency Virus
INH	Isoniazid
LJ	Lowenstein-Jensen
MDR	Multi Drug Resistant
MTB	<i>Mycobacterium tuberculosis</i>
MTBC/ MTC	<i>Mycobacterium tuberculosis</i> Complex
MUT	Mutation Probe
NaOH-NALC	<i>N</i> -acetyl-L-cysteine–NaOH
NCCLS	National Committee for Clinical Laboratory Standards
NTC	National Tuberculosis Centre
NTM	Non Tuberculosis Mycobacteria
NTP	National Tuberculosis Program
PCR	Polymerase Chain Reaction
RIF	Rifampicin
RNA	Ribonucleic acid
TB	Tuberculosis
WHO	World Health Organization
WT	Wild type Probe
XDR	Extensively Drug Resistant